Chemo Pharma Laboratories Limited

As of June 30, 2025, Chemo Pharma Laboratories Limited trades at a trailing price-to-earnings ratio of 78.83.

These figures are as of June 30, 2025. Chemo Pharma Laboratories Limited trades at an EV/FCF ratio of 32,135.09, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Chemo Pharma Laboratories Limited maintains a current ratio of 1,339.32, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025. Return on invested capital (ROIC) comes in at 0.59 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on capital employed (ROCE) is 82.76, useful for judging operating efficiency across full business cycles.

As of the close on November 27, 2025, Chemo Pharma Laboratories Limited's stock has gained approximately 33.88% over the past 52 weeks. The 50-day moving average sits at 120.35, while the 200-day moving average is 117.67.

As of June 30, 2025, Chemo Pharma Laboratories Limited has an Altman Z-Score of 157.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.